



ATTORNEY'S DOCKET NO. C01039.70053.US

#10  
B  
1-22-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Krieg et al.  
Serial No.: 09/931,583  
Confirmation No.: 2288  
Filed: August 16, 2001  
For: METHODS AND PRODUCTS FOR TREATING HIV INFECTION  
Examiner: Dave Nguyen  
Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 13<sup>th</sup> day of January, 2003.

*Yvonne M. Lingb*  
Yvonne M. Lingb

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JAN 22 2003

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement dated December 17, 2002 (Paper No. 9), Applicants hereby request entry of the following Election.

ELECTION

Applicants hereby elect the claims of Group I (claims 1-39 and 54, drawn to combination therapy of treating an HIV-infected patient). As further required by the Examiner upon election of Group I, Applicants further elect the following specific species:

- protease inhibitors, as recited in claim 7;
- anti-HIV therapy is terminated at least one week after the initial administration of CpG, as recited in claim 16; and
- an adjuvant-type CpG nucleic acid SEQ ID NO:29 (TCGTCGTTTTGTCGTTTTGTCGTT), as recited in claim 3.